Tag: Innovation

Patent granted to Valfix Medical for its percutaneous valve and replacement...

Valix Medical has received a US patent—10,278,820 (percutaneous valve repair and replacement)—for its heart valve repair and replacement technology. A press release reports that...

Robotic PCI company adds interventional cardiology experts to its medical advisory...

Robocath has announced that that the well-known interventional cardiologists Michael Haude, Faziel Lorgat, and Holger Nef have joined its medical advisory board. Founded in...

Philips announces new advanced automation capabilities for its EPIQ CVx and...

A Philips press release reports both the EPIQ CVx and EPIQ CVxi now include automated applications for 2D assessment of the heart, as well...

Nearly 50% of treatment strategies would change with use of investigational...

New data show that the use of the investigational HeartFlow Planner—a real-time, non-invasive interactive planning tool—led to a change in treatment strategy in 45% of...

DSM and SAT enter partnership to develop the first next-generation heart...

Royal DSM is to collaborate with Strait Access Technologies (SAT) to develop the world’s first durable and cost-effective transcatheter replacement heart valves with polymeric...

TVT 2019: Purpose-designed temporary pacing guidewire has potential to make implantation...

Speaking during an innovation session at TVT 2019 (12-15 June, Chicago, USA), Mark Hensey (Centre for Heart Valve Innovation, St Paul's Hospital, University of...

Early treatment with Helix system improves ejection fraction and symptoms

The Helix biotherapeutic delivery system (Biocardia), which delivers cell therapy to patients within four weeks of a heart attack, led to improved ejection fraction...

US FDA approve EchoMD AutoEF software for calculating left ventricular ejection...

Bay Labs has received US FDA 510(k) clearance for its EchoMD AutoEF software product for the fully automated clip selection and calculation of left...

Caladrius receives FDA regenerative medicine advanced therapy designation for its CD34+...

Caladrius has revealed that the US FDA has granted regenerative medicine advanced therapy (RMAT) designation to its late-stage CD34+ cell therapy programme for the...